(Q35098007)

6 August 2017

1 reference

title

Overview of bladder cancer trials in the European Organization for Research and Treatment (English)

1 reference

6 August 2017

1 reference

Ronald de Wit

1

1 reference

PubMed ID

12673705

6 August 2017

European Organization for Research and Treatment

series ordinal

2

1 reference

PubMed ID

12673705

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

97

1 reference

6 August 2017

2120-2126

1 reference

6 August 2017

8 Suppl

1 reference

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

Mechanisms of synergism between gemcitabine and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Current perspectives in muscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11288

7 January 2021

Identifiers

DOI

10.1002/CNCR.11288

1 reference

6 August 2017

1 reference

PubMed ID

12673705